MMP-2与VEGF_(165)基因mRNA在卵巢癌中表达及相关性研究  

Expression of mRNA of MMP-2 and VEGF165 genes in ovarian cancer and the relationship between them

作　　者：陈颖[1] 赵巍[1] 张岩[1] 蒋宏颉[1] 

机构地区：[1]中国医科大学附属第四临床医院妇科,辽宁沈阳110032

出　　处：《现代肿瘤医学》2009年第6期1151-1153,共3页Journal of Modern Oncology

基　　金：辽宁省教育厅基金(编号:20060961);沈阳市科学技术计划项目(编号:1063230-3-00)

摘　　要：目的:探讨MMP-2和VEGF165基因mRNA表达在卵巢癌发生和演进中的作用。方法:利用RT-PCR方法检测正常卵巢(n=5)、卵巢囊肿(n=5)、卵巢交界性肿瘤(n=9)和上皮性卵巢癌(n=60)中MMP-2和VEGF165基因mRNA表达。结果:MMP-2和VEGF165基因mRNA在卵巢交界性肿瘤和卵巢癌中的表达水平高于正常卵巢和卵巢囊肿(P<0.05),与卵巢癌的临床病理分期呈正相关(P<0.05),而与组织分化程度呈负相关(P<0.05);浆液性卵巢癌中MMP-2和VEGF165基因mRNA表达水平显著高于其他上皮性卵巢癌(P<0.05)。结论:在卵巢癌中MMP-2和VEGF165基因mRNA表达上调,与卵巢癌的发生和病理生物学行为关系密切;MMP-2和VEGF165基因mRNA表达上调参与了卵巢癌的发生,提高了卵巢癌的侵袭转移能力,因此,构成了卵巢癌发生和侵袭的分子基础。Objective：To investigate the role of mRNA expression of MMP -2 and VEGF165 genes in tumorigene sis and progression of ovarian cancer. Methods ： We examined mRNA expression of MMP - 2 and VEGF165 in normal ovary（ n = 5 ） ,ovarian cyst（ n = 5 ） ,ovarian borderline tumor（ n = 9） and epithelial ovarian cancer（ n = 60） by RT- PCR. Results：mRNA expression level of MMP -2 and VEGF165 genes were significantly higher in ovarian borderline tumor and ovarian cancer than that in normal ovary and ovarian cyst（P 〈 0.05 ）. mRNA expression levels of MMP - 2 and VEGF165 gene were positively correlated with clinicopathological staging（ P 〈 0.05 ）, but negatively with histological differentiation（ P 〈 0.05 ）. mRNA expression levels of MMP -2 and VEGF165 gene were significantly higher in ovarian serous cancer than the other ovarian epithelial cancer（P 〈 0.05 ）. Conclusion：Increased expression of MMP -2 and VEGF165 genes are closely associated with tumorigenesis and pathobiologieal behaviors of ovarian cancer. These results suggested that up - regulated expression of MMP - 2 and VEGF165 genes participate in tumorigenesis and progression of epithelial ovarian cancer, which therefore constituted molecular basis of the tumorigenesis and invasion of epithelial ovarian cancer.

关 键 词：卵巢肿瘤 MMP-2基因 VEGF165基因 MRNA表达 

分 类 号：R737.31[医药卫生—肿瘤]